Targeted Leap: Glenmark Pharma Bolsters Oncology Pipeline With Hengrui’s HER2 ADC Deal

Glenmark Pharmaceuticals Ltd has entered into an exclusive licensing agreement with Hengrui Pharma to commercialize a HER2-targeting antibody-drug conjugate (ADC), marking a strategic expansion of its oncology portfolio. The deal, announced on September 24, 2025, includes an upfront payment of USD 18 million to Hengrui, with additional milestone-linked and royalty components expected over the product lifecycle.

Key highlights from the agreement:

- Glenmark secures exclusive rights to develop and market Hengrui’s HER2-targeting ADC in select global markets  
- The upfront payment of USD 18 million reflects Glenmark’s commitment to expanding its biologics pipeline  
- The ADC candidate is currently in Phase II trials for HER2-positive breast and gastric cancers  
- Glenmark will lead regulatory filings, clinical development, and commercialization in India and emerging markets  
- The partnership includes technology transfer and joint R&D initiatives for next-gen oncology assets  

Strategic Significance And Therapeutic Potential

HER2-targeting ADCs represent a cutting-edge approach in oncology, combining monoclonal antibodies with cytotoxic payloads for precision therapy. Glenmark’s entry into this space enhances its competitive positioning in biologics and strengthens its oncology franchise.

The deal aligns with Glenmark’s strategy to diversify beyond generics and build a robust specialty pipeline. It also supports the company’s ambition to become a key player in targeted cancer therapies across Asia, Latin America, and Africa.

Sources: BSE Corporate Filings, Glenmark Investor Relations, Economic Times Pharma Desk, BusinessLine Biotech Tracker.